Fine Barry, Vunjak-Novakovic Gordana
Department of Biomedical Engineering and ‡Department of Medicine, Columbia University, New York, New York 10027, United States.
Department of Biomedical Engineering and Department of Medicine, Columbia University, New York, New York 10027, United States.
ACS Biomater Sci Eng. 2017 Sep 11;3(9):1884-1897. doi: 10.1021/acsbiomaterials.6b00662. Epub 2017 Feb 6.
We provide here an historical context of how studies utilizing engineered human cardiac muscle can complement and in some cases substitute animal and cell models for studies of disease and drug testing. We give an overview of the development of animal models and discuss the ability of novel human tissue models to overcome limited predictive power of cell culture and animal models in studies of drug efficacy and safety. The in vitro generation of cardiac tissue is discussed in the context of state of the art in the field. Finally we describe the assembly of multitissue platforms for more accurate representation of integrated human cardiac physiology and consider the advantages of in silico drug trials to augment our ability to predict drug-drug and organ-organ interactions in humans.
我们在此提供一个历史背景，说明利用工程化人类心肌进行的研究如何在疾病研究和药物测试中补充并在某些情况下替代动物和细胞模型。我们概述了动物模型的发展，并讨论了新型人类组织模型在药物疗效和安全性研究中克服细胞培养和动物模型预测能力有限的能力。本文在该领域现有技术水平的背景下讨论了心脏组织的体外生成。最后，我们描述了多组织平台的组装，以更准确地呈现整合的人类心脏生理学，并考虑了计算机模拟药物试验在增强我们预测人类药物-药物和器官-器官相互作用能力方面的优势。
